Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s disease, diabetic neuropathy, glaucoma, viral infections, chemotherapy-induced peripheral neuropathy and stroke, among others.